PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 2025Pharmaceuticals1 citationsOpen Access

Advances and Challenges in the Development of New and Novel Treatment Strategies for Eosinophilic Esophagitis (EoE)

View Full Paper
IOIvna Akrapovic OlicPŽPiero Marin ŽivkovićIŽIvan Žaja

Key Points

  • The review highlights several therapeutic options for eosinophilic esophagitis (EoE), including new biologic agents.
  • Proton pump inhibitors and dietary elimination are established treatments, while dupilumab offers a promising new approach.
  • Targeting specific immune pathways with biologics has the potential to modify disease processes in EoE.
  • The ultimate objective remains complete disease resolution, necessitating the development of effective agents.

Abstract

Eosinophilic esophagitis (EoE) is a long-term, immune-driven condition of the esophagus, which can lead to severe fibrostenosis of the esophagus, and the aim is to control clinical, endoscopic, and histopathologic disorder activity. Currently, treatment options include the use of proton pump inhibitors, topical steroids, and dietary elimination as basic treatments; however, the introduction of dupilumab has provided an additional therapeutic approach. Numerous biologic agents target specific immune pathways, which are promising pharmacologic options in managing this progressive disease. The final goal is to treat the target, with complete resolution as the final objective. To accomplish this, however, effective agents capable of modifying the disease process are required. In this review, we aimed to provide an overall review of EoE therapeutics options, as well as the benefits and safety of new treatment strategies for EoE.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Olic et al. (2025) studied this question.

synapsesocial.com/papers/68d44a4031b076d99fa5390ehttps://doi.org/10.3390/ph18091359
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children2025 · 15 citations
  2. 2Management guideline for the off-label use of medicine in China (2021)2022 · 15 citations
  3. 3Microbiome in Eosinophilic Esophagitis—Metagenomic, Metatranscriptomic, and Metabolomic Changes: A Systematic Review2021 · 22 citations
  4. 4Beneficial effect of Lactococcus lactis NCC 2287 in a murine model of eosinophilic esophagitis2016 · 38 citations
  5. 5The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs2024 · 19 citations